Glonghui, December 19 | According to the Dongwu Securities Research Report, considering the launch of new products with innovative attributes of Lizhu Group (000513.SZ), it will bring about faster performance growth, high barriers to complex formulations and exclusive patented products, steady growth in main business, and the company's current low valuation, covering the “buy” rating for the first time. The company accelerated implementation of its high-end pharmaceutical and biopharmaceutical pipelines in 2023-2025, and its innovative attributes have not yet been reflected in the current valuation. Of these, 6 key R&D products have been launched in the past 3-4 years, and are expected to contribute a total of about 6.5 billion yuan to peak sales. In addition, the company's Simeglutide diabetes indications are expected to be produced in 24Q2, and weight loss indications are submitted to IND by the end of 23. The dual market space corresponding to diabetes and weight loss exceeds 100 billion yuan. The bank predicts that its sales will peak at 2 billion yuan.
研报掘金丨东吴证券：丽珠集团主营业务增长稳健，首予“买入”评级
Research Report Nuggets: Dongwu Securities: Livzon Group's main business is growing steadily, giving it the first “buy” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.